Article | 2026 ARVO

Video: Preclinical Data Highlights Potential of VLTR-559 for Wet AMD

“We are really excited about these preclinical pharmacology results, and we believe VLTR-559 is on track to demonstrate superior durability with a reliable 6-month treatment protocol for patients with wet AMD,” Dr. Livia Brier said in her ARVO presentation.